Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Debt: 2010-2024

Historic Non-Current Debt for Cytokinetics (CYTK) over the last 11 years, with Dec 2024 value amounting to $93.2 million.

  • Cytokinetics' Non-Current Debt rose 70.66% to $158.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.7 million, marking a year-over-year increase of 70.66%. This contributed to the annual value of $93.2 million for FY2024, which is 59.68% up from last year.
  • According to the latest figures from FY2024, Cytokinetics' Non-Current Debt is $93.2 million, which was up 59.68% from $58.4 million recorded in FY2023.
  • Over the past 5 years, Cytokinetics' Non-Current Debt peaked at $93.2 million during FY2024, and registered a low of $46.2 million during FY2020.
  • For the 3-year period, Cytokinetics' Non-Current Debt averaged around $71.8 million, with its median value being $63.8 million (2022).
  • In the last 5 years, Cytokinetics' Non-Current Debt decreased by 8.50% in 2023 and then skyrocketed by 59.68% in 2024.
  • Yearly analysis of 5 years shows Cytokinetics' Non-Current Debt stood at $46.2 million in 2020, then climbed by 2.51% to $47.4 million in 2021, then surged by 34.71% to $63.8 million in 2022, then decreased by 8.50% to $58.4 million in 2023, then soared by 59.68% to $93.2 million in 2024.